Such a Deal, Late-Phase
The cliché is that late-stage deals are necessarily expensive. Genentech is showing they don't have to be, lowering its cost of access to drugs by weighting most of its payments towards equity and milestones--and buying the drugs others pass over as too risky.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.